On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > REGULATORY
REGULATORY
- MHLW to Target 75% Generic Share for Welfare Recipients
March 10, 2015
- MHLW’s Panel on Orphan Cancer Holds First Meeting; Draft Report Expected This Summer
March 10, 2015
- Editor’s Pick: Five Healthcare News Headlines for Feb. 23 - March 8
March 9, 2015
- New Dosage Added to Taxol for Gastric Cancer Treatment
March 9, 2015
- Gilead’s Sofosbuvir Likely to Get Japan Greenlight as Early as March-End
March 6, 2015
- Govt Preparing Environment to Deliver Japanese-Originated Drugs: Amari
March 6, 2015
- Aso Shrugs Off Question on Ibuki’s Annual NHI Price Revision Remarks
March 6, 2015
- Ishin Submits Bill to Optimize Clinical Research
March 5, 2015
- NCGM Opts Out of Special Mixed Care Scheme in Tokyo Economic Zone
March 5, 2015
- Orphan Drugs for More than 50,000 Patients Can Be Developed under New Scheme
March 3, 2015
- Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable
March 3, 2015
- MHLW Won’t Order Novartis to Revise Package Inserts over Delayed ADR Reports, Urges Firms to Inspect Safety Control Regime
March 2, 2015
- PMDA Evaluating Sitagliptin for Risk of Thrombocytopenia
March 2, 2015
- Novartis Slapped with 15 Day Biz Suspension over Flawed ADR Reporting
February 27, 2015
- PAFSC Second Committee Backs Approval of Celgene’s Pomalidomide
February 27, 2015
- Roundtable Discussion for Healthcare Policy for 2035 Kicked Off
February 27, 2015
- MHLW OKs 60 New APIs in 2014, Doubling from Year Ago
February 26, 2015
- MHLW Prods Self-Inspections at Insurance Pharmacies after Medication History Fuss
February 25, 2015
- Drug Price Settlement Rate at 76.2% in December: MHLW
February 24, 2015
- Shelved Decision on Xarelto Recommendation Doesn’t Mean Disapproval: MHLW
February 24, 2015
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…